irofulven has been researched along with Lassitude in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| DeVore, RF; Dowell, JE; Johnson, DH; Krozely, P; McCullough, N; Rogers, JS; Shyr, Y | 1 |
| Alberti, D; Arzoomanian, R; Bailey, H; Binger, K; Feierabend, C; MacDonald, J; Marnocha, R; Smith, C; Smith, S; Steele, T; Thomas, JP; Tutsch, KD; Wilding, G | 1 |
2 trial(s) available for irofulven and Lassitude
| Article | Year |
|---|---|
A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with advanced non-small cell cancer previously treated with chemotherapy.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Carcinoma, Non-Small-Cell Lung; Drug Evaluation; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Sesquiterpenes; Thrombocytopenia; Toxicity Tests; Treatment Outcome; Vomiting | 2001 |
Phase I clinical and pharmacokinetic trial of irofulven.
Topics: Acidosis; Aged; Anorexia; Antineoplastic Agents, Alkylating; Dose-Response Relationship, Drug; Fatigue; Female; Half-Life; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Sesquiterpenes; Vomiting | 2001 |